$PHAT News
Last published 1d ago
- 1d agoPHATGUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - PHATHOM PHARMACEUTICALS INCEarnings Call TranscriptsHello, everyone. This is Yatin Suneja, one of the biotech analysts at Guggenheim. It is my pleasure to welcome Stephen Basta, who is the president and chief executive officer of Fathom. We will be chatting with him on al
- 1w agoPHATPhathom Pharmaceuticals to Participate in November Investor ConferencesGlobeNewswireFLORHAM PARK, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI)
- 1w agoPHATPhathom Pharmaceuticals Announces Eligible Commercially Insured Patients May Now Pay as Little as $0 for VOQUEZNA® (vonoprazan) Tablets Exclusively at BlinkRxGlobeNewswirePotential to pay as little as $0 per fill for VOQUEZNA, plus free home delivery and prior authorization support, makes it simpler for GERD patients to get the medicine their doctor prescribed A Media Snippet
- 1w agoPHATPhathom Pharmaceuticals, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoPHATPhathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireOver 2 million total VOQUEZNA® prescriptions filled through October 16, 2026Q3 2026 net revenues of $84.7 million increased 71% vs. Q3 2025 and 14% vs. Q2 2026Generated positive operating cash flow for the second
- 2w agoPHATPhathom Pharmaceuticals Provides Update on FDA LitigationGlobeNewswireFLORHAM PARK, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI)
- 2w agoPHATPhathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDAGlobeNewswireFLORHAM PARK, N.J., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI)
- 3w agoPHATPhathom Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide Business Update on Thursday, October 29, 2026GlobeNewswireFLORHAM PARK, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI)
- 1mo agoPHATPhathom Pharmaceuticals Highlights New Cost-Effectiveness Data and Growing Clinical Interest in VOQUEZNA® (vonoprazan) at ACG 2026GlobeNewswireNew analysis projects VOQUEZNA® (vonoprazan) to provide meaningful economic value and be cost-effective vs. proton pump inhibitors (PPIs) for adults with Erosive GERD, with potential cost savings at net price based on
- 1mo agoPHATPhathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific MeetingGlobeNewswireThree scientific presentations will highlight new analyses of VOQUEZNA® (vonoprazan) in GERD, including real-world patient characteristics, efficacy across BMI subgroups, and cost-effectiveness in Erosive Esophagitis
- 2mo agoPHATPhathom Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswireFLORHAM PARK, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI)
- 3mo agoPHATPhathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire~1.7 million total VOQUEZNA® prescriptions filled to dateRecord Q2 2026 net revenues of $74.3 million, increased 88% vs. Q2 2025 and 27% vs. Q1 2026Q2 operating expenses of $63.1 million, reduced by 33% vs. Q2
- 3mo agoPHATPhathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026GlobeNewswireFLORHAM PARK, N.J., July 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI)
- 4mo agoPHATPhathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)GlobeNewswireThis trial is the first large, placebo-controlled clinical trial of an acid suppression treatment in EoETopline results for the double-blind 12-week treatment portion of the study are expected in Q4 of 2026 FLORHAM
- 5mo agoPHATGoldman Sachs 47th Annual Global Healthcare Conference - Goldman SachsEarnings Call TranscriptsGood afternoon, and thank you for joining us for this session. I'm Paul Choi, and I cover the SmithCat biotech sector here at the firm. It's our pleasure to have Fathom Pharmaceuticals here joining us for this section. I
- 5mo agoPHATPhathom Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswireFLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI)
- 5mo agoPHATPhathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual MeetingGlobeNewswire31 vonoprazan-related clinical abstracts presented at Digestive Disease Week (DDW) 2026, including 28 independent analyses across GI conditions and three Phathom-sponsored clinical research abstractsIndependent
- 6mo agoPHATPhathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual MeetingGlobeNewswireFLORHAM PARK, N.J., May 01, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI)
- 6mo agoPHATPhathom Pharmaceuticals – First Quarter 2026 Earnings Conference Call - PHATHOM PHARMACEUTICALS INCEarnings Call TranscriptsHello and welcome to the Fathom Pharmaceuticals first quarter 2026 earnings result call. At this time, all participants are in a listen-only mode. After the presentation, there will be a question and answer session. To a
- 6mo agoPHATPhathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire~1.35 million total VOQUEZNA® prescriptions filled to date$58.3 million in Q1 net revenues, a 104% increase year-over-yearQ1 operating expenses of $61.8 million; non-GAAP operating expenses of $56.2 million and net
- 6mo agoPHATPhathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026GlobeNewswireManagement to host conference call on Thursday, April 30, 2026, at 8:00 am EDT FLORHAM PARK, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on
- 7mo agoPHATPhathom Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswireFLORHAM PARK, N.J., April 06, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI)
- 8mo agoRDHLCPIXPHATH. pylori Infections Market in the 6MM to Observe Stupendous Growth at a CAGR of 9.5% During the Forecast Period (2026-2036) | DelveInsightPR NewswireRecently published H. pylori Infections Market Insights report includes a comprehensive understanding of current treatment practices, H. pylori...
- 8mo agoPHATPhathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial GuidanceGlobeNewswireOver 1.1 million total VOQUEZNA® prescriptions filled to date $57.6 million in Q4 net revenues; $175.1 million in FY 2025 net revenues, a 217% increase from FY 2024 Q4 operating expenses of $55.9 million;
- 8mo agoPHATPhathom Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswireFLORHAM PARK, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI)
- 8mo agoPHATPhathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026GlobeNewswireFLORHAM PARK, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases,
- 9mo agoPHATPhathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026GlobeNewswireFLORHAM PARK, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI)
- 10mo agoPHATPhathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswireFLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI)
- 10mo agoPHATPhathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswireFLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI)
- 10mo agoPHATPhathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswireFLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI)
- 1y agoPHATApproval of Voquezna, Nda #215151 (Labeling)FDA Approved DrugsApproval Date: 11/06/2025; Drug Name: Voquezna, Nda #215151; Active Ingredients: VONOPRAZAN FUMARATE; Company: Phathom; Submission Status: Approval; Submission Classification: Labeling; Application Number: 215151
- 1y agoPHATPhathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)GlobeNewswireFirst patient dosed, with topline results expected in 2027pHalcon-EoE-201 is the first large, well-controlled clinical trial of an acid secretory treatment in EoE FLORHAM PARK, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) --
- 1y agoPHATPhathom Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswireFLORHAM PARK, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI)
- 1y agoPHATPhathom Pharmaceuticals – Third Quarter 2025 Earnings Conference Call - PHATHOM PHARMACEUTICALS INCEarnings Call TranscriptsHello and welcome to the Fathom Pharmaceuticals third quarter 2025 earnings results call. At this time all participants are in a listen only mode. After the presentation there will be a question and answer session. To ra
- 1y agoPHATPhathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireOver 790,000 total VOQUEZNA® prescriptions filled to dateFilled VOQUEZNA prescriptions increased 28% from Q2 2025Net revenues of $49.5 million, up 25% quarter over quarter, and cash operating expenses down 43%
- 1y agoPHATPhathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux DiseaseGlobeNewswireData published in the American Journal of Gastroenterology showed rapid and sustained relief of nighttime gastroesophageal reflux disease (GERD) symptoms in patients treated with VOQUEZNA, including clinically meaningful
- 1y agoPHATPhathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific MeetingGlobeNewswireFLORHAM PARK, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI)
- 1y agoPHATPhathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025GlobeNewswireManagement to host conference call on Thursday, October 30, 2025, at 8:00 am EDT FLORHAM PARK, N.J., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused
- 1y agoPHATPhathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business OfficerGlobeNewswireSanjeev Narula brings proven success in scaling commercial-stage biopharma companies with expertise in capital and investor strategies, M&A, and operational excellenceAppointment strengthens Phathom's leadership team
- 1y agoPHATPhathom Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswireFLORHAM PARK, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI)
- 1y agoPHATPhathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder's Ownership Following Administrative Change to 13D FilingGlobeNewswireFLORHAM PARK, N.J., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), today clarified that a Schedule 13D filing by Frazier Life Sciences, which is expected to be filed later today, August
- 1y agoPHATPhathom Pharmaceuticals, Inc. (PHAT) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoPHATPhathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewswireOver 580,000 VOQUEZNA® prescriptions filled to date, reflecting 49% growth since last earnings reportNet revenues of $39.5 million reported for Q2Full-year 2025 revenue guidance of $165 million to $175
- 1y agoPHATPhathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025GlobeNewswireManagement to host conference call on Thursday, August 7, 2025, at 8:00 am EDT FLORHAM PARK, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on
- 1y agoPHATPhathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireFLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI)
- 1y agoPHATSAGEPhathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate SecretaryGlobeNewswireFLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI)
- 1y agoPHATPhathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032GlobeNewswireFLORHAM PARK, N.J., June 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI)
- 1y agoPHATApproval of Voquezna Dual Pak, Nda #215153 (Labeling)FDA Approved DrugsApproval Date: 06/12/2025; Drug Name: Voquezna Dual Pak, Nda #215153; Active Ingredients: AMOXICILLIN; VONOPRAZAN FUMARATE; Company: Phathom; Submission Status: Approval; Submission Classification: Labeling; Application Number: 215153
- 1y agoPHATApproval of Voquezna Triple Pak, Nda #215152 (Labeling)FDA Approved DrugsApproval Date: 06/12/2025; Drug Name: Voquezna Triple Pak, Nda #215152; Active Ingredients: AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE; Company: Phathom; Submission Status: Approval; Submission Classification: Labeling; Application Number: 215152
- 1y agoPHATPhathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032GlobeNewswireFLORHAM PARK, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) today announced that the U.S. Food and Drug Administration (FDA) has approved Phathom's Citizen Petition filed on